| Trial ID: | L1249 |
| Source ID: | NCT02459288
|
| Associated Drug: |
Clopidogrel First
|
| Title: |
Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients
|
| Acronym: |
APROVE-CKD
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Acute Coronary Syndrome|Chronic Kidney Disease|End-Stage Renal Disease
|
| Interventions: |
DRUG: Clopidogrel first|DRUG: Ticagrelor first
|
| Outcome Measures: |
Primary: platelet VerifyNow inhibition rate and Platelet Residual Unit (PRU) values changes, baseline, 2 weeks and 4 weeks later (compare cross over effect) | Secondary: Major bleeding events, assessed by TIMI bleeding score: mild, moderate and severe; the transfusion of packed red blood cell amount; decreased count in Hb (\>2.5), 1 year | Other: Myocardial infarction, 1 year|emergent condition with hospitalization need, Number of subjects with an emergent condition that required hospitalization, 30 days
|
| Sponsor/Collaborators: |
Sponsor: Ping-Yen Liu
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2014-01
|
| Completion Date: |
2015-12
|
| Results First Posted: |
|
| Last Update Posted: |
2015-06-02
|
| Locations: |
Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, 704, Taiwan
|
| URL: |
https://clinicaltrials.gov/show/NCT02459288
|
